Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human CD19 Protein, DDK/His-tagged

Cat.No. : CD19-409H
Product Overview : Recombinant Human CD19(Pro20 – Lys291), transcript variant 2, fused with DDK/His tag at C-terminal was expressed in HEK293.
  • Specification
  • Gene Information
  • Related Products
Description : Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Source : HEK293
Species : Human
Tag : DDK/His
Form : 1 x PBS, pH7.4, 10% glycerol.
Molecular Mass : 32 kDa
Protein length : Pro20 – Lys291
Purity : > 80% as determined by SDS-PAGE and Coomassie blue staining
Concentration : >50 ug/mL as determined by microplate BCA method
Gene Name : CD19 CD19 molecule [ Homo sapiens ]
Official Symbol : CD19
Synonyms : CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
Gene ID : 930
mRNA Refseq : NM_001770
Protein Refseq : NP_001761
MIM : 107265
UniProt ID : P15391

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
How does CAR-T cell therapy work to combat CD19-expressing cancers? 02/11/2023

CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

Are there any diseases associated with CD19 dysfunction? 12/07/2022

CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

What are the potential side effects of CAR-T cell therapy targeting CD19? 01/26/2022

Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

What are some CD19-expressing malignancies that CAR-T cell therapy can target? 07/17/2021

CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

How effective is CAR-T cell therapy in treating CD19-expressing cancers? 08/26/2019

CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.

Customer Reviews (3)

Write a review
Reviews
01/02/2023

    The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

    08/18/2022

      This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

      06/29/2016

        Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

        Ask a Question for All CD19 Products

        Required fields are marked with *

        My Review for All CD19 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends